30

Hangzhou Bio-Sincerity Pharma-Tech Co LtdSHE 301096 Stock Report

Last reporting period 30 Sep, 2023

Updated 08 Nov, 2024

Last price

Market cap $B

1.557

Small

Exchange

XSHE - Shenzhen Stock Exchange

301096.SZ Stock Analysis

30

Uncovered

Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

62/100

Moderate score

Market cap $B

1.557

Dividend yield

0.48 %

Shares outstanding

108.17 B

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. engages in the research and development of medicine and medical technology. The company is headquartered in Hangzhou, Zhejiang and currently employs 765 full-time employees. The company went IPO on 2021-12-20. The services provided by the Company mainly include entrusted R&D of pharmaceutical technology and transformation of independent R&D technological achievements. The entrusted R&D business provides integrated pharmaceutical R&D services such as pharmaceutical research, clinical trial and registration application for major pharmaceutical enterprises and pharmaceutical R&D investment enterprises. The transformation business of independent R&D technological achievements is based on the independent project research and development of drug R&D platform, and actively promote the transformation of independent R&D technological achievements after obtaining phased R&D achievements.

View Section: Eyestock Rating